US5962490A
(en)
*
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
BR9812258A
(pt)
|
1997-04-28 |
2000-07-25 |
Texas Biotechnology Corp |
Sulfonamidas para tratamento de distúrbios mediados por endotelina
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
PL193215B1
(pl)
|
1997-10-17 |
2007-01-31 |
Eurogene Ltd |
Zastosowanie lipofilnych inhibitorów układu renina-angiotensyna
|
KR20010041916A
(ko)
*
|
1998-03-17 |
2001-05-25 |
로즈 암스트롱, 크리스틴 에이. 트러트웨인 |
스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
|
US6638937B2
(en)
|
1998-07-06 |
2003-10-28 |
Bristol-Myers Squibb Co. |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
CA2336714A1
(en)
|
1998-07-06 |
2000-01-13 |
Bristol-Myers Squibb Company |
Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
|
MY125533A
(en)
*
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
EP1237888B1
(de)
*
|
1999-12-15 |
2006-09-13 |
Bristol-Myers Squibb Company |
Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
|
ATE360628T1
(de)
|
1999-12-31 |
2007-05-15 |
Encysive Pharmaceuticals Inc |
Sulfonamide und deren derivate als modulatoren der endothelin-aktivität
|
US7645898B2
(en)
*
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7855229B2
(en)
*
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US6639082B2
(en)
*
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
US6573285B2
(en)
*
|
2000-12-21 |
2003-06-03 |
Bristol-Myers Squibb Co. |
Method for preventing or treating pain by administering an endothelin antagonist
|
WO2002083130A1
(en)
*
|
2001-04-16 |
2002-10-24 |
Bristol-Myers Squibb Company |
Enantiomers of n-[[2'-[[(4,5-dimethyl-3-isoxazolyl) amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-n,3,3-trimethylbutanamide
|
ATE544750T1
(de)
|
2001-09-21 |
2012-02-15 |
Bristol Myers Squibb Co |
Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
|
HUP0700151A2
(en)
*
|
2001-10-18 |
2007-05-29 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US20070161608A1
(en)
*
|
2001-12-06 |
2007-07-12 |
Dalton James T |
Selective androgen receptor modulators for treating muscle wasting
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
TW200307539A
(en)
*
|
2002-02-01 |
2003-12-16 |
Bristol Myers Squibb Co |
Cycloalkyl inhibitors of potassium channel function
|
US7772433B2
(en)
*
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
US7435824B2
(en)
*
|
2002-04-19 |
2008-10-14 |
Bristol-Myers Squibb Company |
Prodrugs of potassium channel inhibitors
|
TW200403058A
(en)
*
|
2002-04-19 |
2004-03-01 |
Bristol Myers Squibb Co |
Heterocyclo inhibitors of potassium channel function
|
US7405234B2
(en)
*
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
AU2003276648A1
(en)
*
|
2002-06-17 |
2003-12-31 |
Bristol-Myers Squibb Company |
Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
|
MY139563A
(en)
*
|
2002-09-04 |
2009-10-30 |
Bristol Myers Squibb Co |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
WO2004021997A2
(en)
*
|
2002-09-06 |
2004-03-18 |
Microbia, Inc. |
Inhibitors of fungal invasion
|
DE60332856D1
(de)
*
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
EP1567487A4
(de)
*
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
|
US8309603B2
(en)
*
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
JP2006516620A
(ja)
*
|
2003-01-24 |
2006-07-06 |
ブリストル−マイヤーズ スクイブ カンパニー |
甲状腺受容体におけるシクロアルキル含有アニリドリガンド
|
CL2004000545A1
(es)
*
|
2003-03-18 |
2005-01-28 |
Pharmacia Corp Sa Organizada B |
Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US6846836B2
(en)
*
|
2003-04-18 |
2005-01-25 |
Bristol-Myers Squibb Company |
N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7256208B2
(en)
*
|
2003-11-13 |
2007-08-14 |
Bristol-Myers Squibb Company |
Monocyclic N-Aryl hydantoin modulators of androgen receptor function
|
US20050182105A1
(en)
*
|
2004-02-04 |
2005-08-18 |
Nirschl Alexandra A. |
Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7388027B2
(en)
*
|
2004-03-04 |
2008-06-17 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7772232B2
(en)
*
|
2004-04-15 |
2010-08-10 |
Bristol-Myers Squibb Company |
Quinazolinyl compounds as inhibitors of potassium channel function
|
US7550499B2
(en)
*
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
EP1750862B1
(de)
|
2004-06-04 |
2011-01-05 |
Teva Pharmaceutical Industries Ltd. |
Irbesartan enthaltende pharmazeutische zusammensetzung
|
US20110237664A1
(en)
*
|
2004-06-07 |
2011-09-29 |
Dalton James T |
Selective androgen receptor modulators for treating diabetes
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US7754755B2
(en)
*
|
2004-09-23 |
2010-07-13 |
Bristol-Myers Squibb Company |
Inhibitors of 15-lipoxygenase
|
US7429611B2
(en)
|
2004-09-23 |
2008-09-30 |
Bristol-Myers Squibb Company |
Indole inhibitors of 15-lipoxygenase
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US8143425B2
(en)
*
|
2004-10-12 |
2012-03-27 |
Bristol-Myers Squibb Company |
Heterocyclic aromatic compounds useful as growth hormone secretagogues
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US20060128726A1
(en)
*
|
2004-11-24 |
2006-06-15 |
Xuebao Wang |
Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
WO2006076597A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
*
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7361766B2
(en)
|
2005-01-12 |
2008-04-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
CN101137412B
(zh)
|
2005-01-13 |
2012-11-07 |
布里斯托尔-迈尔斯·斯奎布公司 |
用作凝血因子XIa抑制剂的取代的二芳基化合物
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
EP1954696B1
(de)
*
|
2005-01-19 |
2011-02-23 |
Bristol-Myers Squibb Company |
2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminderivate und verwandte verbindungen als p2y1-rezeptor-hemmer zur behandlung thromboembolischer erkrankungen
|
ATE421518T1
(de)
*
|
2005-02-10 |
2009-02-15 |
Bristol Myers Squibb Co |
Dihydrochinazolinone als 5ht-modulatoren
|
US20060235028A1
(en)
|
2005-04-14 |
2006-10-19 |
Li James J |
Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
JP2008542292A
(ja)
*
|
2005-05-26 |
2008-11-27 |
ブリストル−マイヤーズ スクイブ カンパニー |
N末端修飾glp−1受容体モジュレーター
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
AU2006261828A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
US7700620B2
(en)
*
|
2005-06-27 |
2010-04-20 |
Bristol-Myers Squibb Company |
C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
ATE502924T1
(de)
|
2005-06-27 |
2011-04-15 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
|
WO2007002634A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
EA200800430A1
(ru)
*
|
2005-07-28 |
2008-06-30 |
Бристол-Маерс Сквибб Компани |
Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
|
EP1757290A1
(de)
|
2005-08-16 |
2007-02-28 |
Zentaris GmbH |
Triazolderivate als Liganden der Wachstumshormonrezeptoren
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
US7534804B2
(en)
*
|
2005-08-24 |
2009-05-19 |
Bristol-Myers Squibb Company |
Benzoxazole inhibitors of 15-lipoxygenase
|
WO2007027454A1
(en)
*
|
2005-08-30 |
2007-03-08 |
Bristol-Myers Squibb Company |
Heterocyclic dihydropyrimidine compounds
|
WO2007027582A2
(en)
|
2005-08-31 |
2007-03-08 |
University Of Tennessee Research Foundation |
Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
US20070238669A1
(en)
*
|
2006-01-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US20100022568A1
(en)
*
|
2006-04-13 |
2010-01-28 |
Actelion Pharmaceeuticals Ltd. |
Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
|
EP2021014A1
(de)
*
|
2006-05-26 |
2009-02-11 |
Brystol-Myers Squibb Company |
Glp-1-rezeptor-modulatoren mit verzögerter freisetzung
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
PT2038252T
(pt)
|
2006-07-12 |
2016-12-16 |
Univ Tennessee Res Found |
Acilanilidos substituidos e métodos de utilização dos mesmos
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
EA016853B1
(ru)
|
2006-08-24 |
2012-08-30 |
Юниверсити Оф Теннесси Рисерч Фаундейшн |
Замещенные ациланилиды и их применение
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
MX2009007831A
(es)
|
2007-01-22 |
2010-01-15 |
Gtx Inc |
Agentes de union de receptor nuclear.
|
US9604931B2
(en)
|
2007-01-22 |
2017-03-28 |
Gtx, Inc. |
Nuclear receptor binding agents
|
US9623021B2
(en)
*
|
2007-01-22 |
2017-04-18 |
Gtx, Inc. |
Nuclear receptor binding agents
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
EP2474549A1
(de)
|
2007-04-17 |
2012-07-11 |
Bristol-Myers Squibb Company |
Kondensierte heterocyclische als Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-Typ I
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
CN101663293B
(zh)
*
|
2007-04-23 |
2013-07-31 |
塞诺菲-安万特股份有限公司 |
作为p2y12拮抗剂的喹啉-甲酰胺衍生物
|
WO2008137435A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Bristol-Myers Squibb Company |
[6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
|
CN101668759A
(zh)
*
|
2007-05-04 |
2010-03-10 |
百时美施贵宝公司 |
[6,5]-双环gpr119g蛋白-偶合受体激动剂
|
JP2010528023A
(ja)
*
|
2007-05-18 |
2010-08-19 |
ブリストル−マイヤーズ スクイブ カンパニー |
Sglt2阻害剤の結晶構造およびその製造方法
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
EA016595B1
(ru)
*
|
2007-07-17 |
2012-06-29 |
Бристол-Маерс Сквибб Компани |
Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения
|
JP2010534722A
(ja)
*
|
2007-07-27 |
2010-11-11 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼ活性化薬およびその使用方法
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
JP5504171B2
(ja)
|
2007-12-26 |
2014-05-28 |
サノフイ |
P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
|
PE20091364A1
(es)
|
2008-01-17 |
2009-10-13 |
Novartis Ag |
Proceso para la preparacion de inhibidores de nep
|
EP2103602A1
(de)
|
2008-03-17 |
2009-09-23 |
AEterna Zentaris GmbH |
Neuartige 1,2,4-Triazol-Derivate und Herstellungsverfahren dafür
|
CN102099340A
(zh)
|
2008-05-19 |
2011-06-15 |
先灵公司 |
作为因子ixa抑制剂的杂环化合物
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
TW201006821A
(en)
|
2008-07-16 |
2010-02-16 |
Bristol Myers Squibb Co |
Pyridone and pyridazone analogues as GPR119 modulators
|
CA2756786A1
(en)
|
2009-03-27 |
2010-09-30 |
Bristol-Myers Squibb Company |
Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
|
EP2442791B1
(de)
|
2009-06-16 |
2019-11-27 |
Pfizer Inc. |
Darreichungsformen von apixaban
|
EP2462123B1
(de)
|
2009-08-04 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
4,5,6-trisubstituierte pyrimidin- derivate als factor ixa inhibitoren
|
DK2498759T3
(en)
|
2009-11-13 |
2018-11-26 |
Astrazeneca Ab |
TABLE FORMULATIONS WITH IMMEDIATE RELEASE
|
JP5775522B2
(ja)
|
2009-11-13 |
2015-09-09 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
二層錠製剤
|
RU2564901C2
(ru)
|
2009-11-13 |
2015-10-10 |
Бристол-Майерс Сквибб Кампани |
Композиции метформина с уменьшенной массой
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
JP2013523822A
(ja)
|
2010-04-08 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
Gpr119修飾因子としてのピリミジニルピペリジニルオキシピリジノ類似体
|
JP2013523894A
(ja)
|
2010-04-14 |
2013-06-17 |
ブリストル−マイヤーズ スクイブ カンパニー |
新規グルコキナーゼアクチベーターおよびその使用方法
|
WO2011140160A1
(en)
|
2010-05-06 |
2011-11-10 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl compounds as gpr119 modulators
|
WO2011140161A1
(en)
|
2010-05-06 |
2011-11-10 |
Bristol-Myers Squibb Company |
Benzofuranyl analogues as gpr119 modulators
|
CA2806780A1
(en)
|
2010-08-23 |
2012-03-01 |
Novartis Ag |
Process for the preparation of intermediates for the manufacture of nep inhibitors
|
EP2431035A1
(de)
|
2010-09-16 |
2012-03-21 |
Æterna Zentaris GmbH |
Neue Triazolderivate mit verbesserter Rezeptoraktivität und Bioverfügbarkeitseigenschaften als Ghrelin-Antagonisten der Wachstumshormon-Sekretagogum-Rezeptoren
|
US8993631B2
(en)
|
2010-11-16 |
2015-03-31 |
Novartis Ag |
Method of treating contrast-induced nephropathy
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2013068875A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
2-thiopyrimidinones
|
EP2834238B1
(de)
|
2012-04-06 |
2017-02-01 |
Pfizer Inc. |
Diacylglycerol-acyltransferase-2-hemmer
|
US9174965B2
(en)
|
2012-05-16 |
2015-11-03 |
Bristol-Myers Squibb Company |
Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
|
ES2675314T3
(es)
|
2012-06-11 |
2018-07-10 |
Bristol-Myers Squibb Company |
Profármacos de ácido fosforamídico de 5-[5-fenil-4-(piridin-2-ilmetilamino) quinazolin-2-il] piridin-3-sulfonamida
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
IN2015DN01046A
(de)
|
2012-07-13 |
2015-06-26 |
Gtx Inc |
|
WO2014039411A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
US9499482B2
(en)
|
2012-09-05 |
2016-11-22 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
|
IN2015DN04089A
(de)
*
|
2012-11-14 |
2015-10-09 |
BIAL PORTELA & Cª S A |
|
MX365753B
(es)
|
2012-11-20 |
2019-06-12 |
Lexicon Pharmaceuticals Inc |
Inhibidores del contransportador 1 de sodio glucosa.
|
JP6395798B2
(ja)
|
2013-03-11 |
2018-09-26 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
カリウムイオンチャネル阻害剤としてのピロロトリアジン
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
US9242966B2
(en)
|
2013-03-11 |
2016-01-26 |
Bristol-Myers Squibb Company |
Phthalazines as potassium ion channel inhibitors
|
WO2014143609A1
(en)
|
2013-03-11 |
2014-09-18 |
Bristol-Myers Squibb Company |
Isoquinolines as potassium ion channel inhibitors
|
JP6386527B2
(ja)
|
2013-03-11 |
2018-09-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
カリウムイオンチャネル阻害剤としてのピロロピリダジン
|
WO2015052610A1
(en)
|
2013-10-09 |
2015-04-16 |
Pfizer Inc. |
Antagonists of prostaglandin ep3 receptor
|
WO2015061272A1
(en)
|
2013-10-22 |
2015-04-30 |
Bristol-Myers Squibb Company |
Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
|
MA39753B1
(fr)
|
2014-03-17 |
2018-10-31 |
Pfizer |
Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
|
PE20161251A1
(es)
|
2014-04-04 |
2016-11-30 |
Pfizer |
Compuestos heteroarilo o arilo biciclicos fusionados y su uso como inhibidores de irak4
|
US9969724B2
(en)
|
2014-04-16 |
2018-05-15 |
Merck Sharp & Dohme Corp. |
Factor IXa inhibitors
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
EP3237401B1
(de)
|
2014-12-22 |
2019-03-06 |
Pfizer Inc |
Antagonisten des prostaglandin-ep3-rezeptors
|
CR20170498A
(es)
|
2015-05-05 |
2018-01-26 |
Pfizer |
2-tiopirimidinonas
|
EP3303303A1
(de)
|
2015-05-29 |
2018-04-11 |
Pfizer Inc |
Neuartige heterocyclische verbindungen als vanin-1-enzym-inhibitoren
|
DK3766885T3
(da)
|
2015-06-17 |
2022-08-01 |
Pfizer |
Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer
|
WO2016203335A1
(en)
|
2015-06-18 |
2016-12-22 |
Pfizer Inc. |
Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
|
BR112018002071A2
(pt)
|
2015-08-13 |
2018-09-18 |
Pfizer |
compostos heteroarílicos ou arílicos fundidos bicíclicos
|
RU2684324C1
(ru)
|
2015-08-27 |
2019-04-08 |
Пфайзер Инк. |
Бициклические конденсированные гетероарильные или арильные соединения в качестве модуляторов IRAK4
|
WO2017037567A1
(en)
|
2015-09-03 |
2017-03-09 |
Pfizer Inc. |
Regulators of frataxin
|
SI3397631T1
(sl)
|
2015-12-29 |
2022-01-31 |
Pfizer Inc. |
Substituirani 3-azabiciklo(3.1.0)heksani kot zaviralci ketoheksokinaze
|
SG11201811161YA
(en)
|
2016-07-14 |
2019-01-30 |
Pfizer |
Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
|
KR102513342B1
(ko)
|
2016-07-22 |
2023-03-22 |
브리스톨-마이어스 스큅 컴퍼니 |
글루코키나제 활성화제 및 그의 사용 방법
|
AR109179A1
(es)
|
2016-08-19 |
2018-11-07 |
Pfizer |
Inhibidores de diacilglicerol aciltransferasa 2
|
EA202091324A1
(ru)
|
2017-11-30 |
2020-10-05 |
Идорсия Фармасьютиклз Лтд |
Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
|
WO2019133445A1
(en)
|
2017-12-28 |
2019-07-04 |
Inception Ibd, Inc. |
Aminothiazoles as inhibitors of vanin-1
|
WO2020016335A1
(en)
|
2018-07-19 |
2020-01-23 |
Astrazeneca Ab |
Methods of treating hfpef employing dapagliflozin and compositions comprising the same
|
AU2019329884B2
(en)
|
2018-08-31 |
2022-01-27 |
Pfizer Inc. |
Combinations for treatment of NASH/NAFLD and related diseases
|
KR20210065974A
(ko)
|
2018-09-26 |
2021-06-04 |
렉시컨 파마슈티컬스 인코퍼레이티드 |
N-(1-((2-(디메틸아미노)에틸)아미노)-2-메틸-1-옥소프로판-2-일)-4-(4-(2-메틸-5-((2s,3r,4r,5s,6r)-3,4,5-트리히드록시-6-(메틸티오)테트라히드로-2h-피란-2-일)벤질)페닐)부탄아미드의 결정질 형태 및 그의 합성 방법
|
WO2020102575A1
(en)
|
2018-11-16 |
2020-05-22 |
Inception Ibd, Inc. |
Heterocyclic aminothiazoles and uses thereof
|
CN113874019A
(zh)
|
2019-05-20 |
2021-12-31 |
辉瑞大药厂 |
用于治疗nash/nafld及相关疾病的包含作为glp-1r激动剂的苯并二氧杂环戊烯的组合
|
TW202115086A
(zh)
|
2019-06-28 |
2021-04-16 |
美商輝瑞大藥廠 |
Bckdk抑制劑
|
EP3990452A1
(de)
|
2019-06-28 |
2022-05-04 |
Pfizer Inc. |
5-(thiophen-2-yl)-1h-tetrazolderivate als bckdk-inhibitoren zur behandlung verschiedener erkrankungen
|
TWI771766B
(zh)
|
2019-10-04 |
2022-07-21 |
美商輝瑞股份有限公司 |
二醯基甘油醯基轉移酶2 抑制劑
|
EP4094759A1
(de)
|
2019-10-30 |
2022-11-30 |
Perfuse Therapeutics, Inc. |
Behandlung von augenkrankheiten unter verwendung von endothelinrezeptor-antagonisten
|
CA3168810A1
(en)
*
|
2020-02-06 |
2021-08-12 |
Perfuse Therapeutics, Inc. |
Compositions for treatment of ocular diseases
|
JP2022058085A
(ja)
|
2020-02-24 |
2022-04-11 |
ファイザー・インク |
ジアシルグリセロールアシルトランスフェラーゼ2阻害剤とアセチル-CoAカルボキシラーゼ阻害剤との組合せ
|
CN116113635A
(zh)
|
2020-06-09 |
2023-05-12 |
辉瑞公司 |
作为黑皮质素4受体拮抗剂的螺环化合物及其用途
|
TW202220672A
(zh)
|
2020-07-27 |
2022-06-01 |
瑞典商阿斯特捷利康公司 |
用達格列淨治療慢性腎臟病之方法
|
AU2022264036A1
(en)
*
|
2021-04-30 |
2023-11-23 |
Perfuse Therapeutics, Inc. |
Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
|
CN117255791A
(zh)
|
2021-06-22 |
2023-12-19 |
亚克医药株式会社 |
化合物、内皮素a受体拮抗剂及医药组合物
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|
WO2023026180A1
(en)
|
2021-08-26 |
2023-03-02 |
Pfizer Inc. |
Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
|
AU2022403203A1
(en)
|
2021-12-01 |
2024-05-02 |
Pfizer Inc. |
3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
|
WO2023105387A1
(en)
|
2021-12-06 |
2023-06-15 |
Pfizer Inc. |
Melanocortin 4 receptor antagonists and uses thereof
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
WO2023169456A1
(en)
|
2022-03-09 |
2023-09-14 |
Gasherbrum Bio , Inc. |
Heterocyclic glp-1 agonists
|
WO2023198140A1
(en)
|
2022-04-14 |
2023-10-19 |
Gasherbrum Bio, Inc. |
Heterocyclic glp-1 agonists
|
WO2024075051A1
(en)
|
2022-10-07 |
2024-04-11 |
Pfizer Inc. |
Hsd17b13 inhibitors and/or degraders
|
WO2024084390A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Compounds for the activation of ampk
|
WO2024084360A1
(en)
|
2022-10-18 |
2024-04-25 |
Pfizer Inc. |
Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
|